In a significant PBS pricing decision, Justice Downes held that the PBS listing of Alphapharm’s generic Descovy® would also trigger statutory price reductions for several of Gilead’s related combination therapies, including Odefsey®, Biktarvy® and Genvoya®, under s 99ACC of the National Health Act.
Two of Pearce IP’s leaders have been recommended by the Lexology Index: Intellectual Property 2026 which honours a small number of leading IP lawyers across 88 countries. CEO and Founder, Naomi Pearce and Executive Helen Macpherson are is recommended for Patents, and Copyright respectively.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 14 August 2026 are set out below…
All of Pearce IP’s New Zealand Executives have been recognised in the 2026 Doyle’s Guide – Leading Intellectual Property Lawyers (New Zealand) rankings. Paul Johns is one of 11 lawyers honoured as a Leading Intellectual Property Lawyer. Sally Paterson is one of 21 lawyers recognised as a Recommended Intellectual Property Lawyer.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 7 August 2026 are set out below…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 31 July 2026 are set out below…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 24 July 2026 are set out below…
How do you protect confidential information before a former employee makes it public? Naomi Pearce and Helen Macpherson discuss a recent Federal Court decision which highlights how quickly Australia’s courts can act when IP rights are at risk.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 17 July 2026 are set out below…
Justice Stellios, sitting as duty judge in the Federal Court of Australia, has granted a mandatory interlocutory injunction requiring RedTail Technology Pty Ltd and its founder and sole director, secretary and shareholder (Richard Pahlavani).
The Full Court of the Federal Court of Australia has delivered its decision in NOCO’s appeal from the primary judge’s decision in The NOCO Company v Brown and Watson International Pty Ltd [2025] FCA 887. The Full Court has dismissed NOCO’s appeal, rejecting NOCO’s challenges on lack of inventive step and the correct priority date for assessing novelty.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 10 July 2026 are set out below…
Shanghai Lytone Biochemicals has failed in its opposition to the grant of Fresh Inset S.A.’s patent application for compositions and articles comprising complexes of 1-methylcyclopropene (1-MCP) and alpha-cyclodextrin (α-CD), which are used to prolong the shelf life of plant products by inhibiting the effects of ethylene.
Pearce IP is pleased to welcome Sarah Dieckmann as an Associate and Foreign Registered Patent Attorney, further strengthening the firm’s specialist capability in biotechnology and life sciences intellectual property.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 3 July 2026 are set out below…
In v2food v Provectus, the Federal Court allowed v2food’s appeal after the opponent filed no evidence and took no active role in the appeal. Although the APO had previously found the claims lacked inventive step, the Court confirmed that on a de novo appeal the opponent still bears the onus — and without evidence, the opposition must fail.
Pearce IP is proud to be recognised by Australasian Lawyer and NZ Lawyer as a Top Specialist Firm in Intellectual Property for 2026 – marking its second consecutive year of recognition. Pearce IP was one of only six firms ranked in intellectual property, and the only standalone IP firm operating across both Australia and New Zealand.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 26 June 2026 are set out below…
Pearce IP continues to deliver on its commitment to set the standard for excellence in the provision of legal and intellectual property services across Australia and New Zealand with the appointment of Sarah Ramsey-Caudle as Senior Associate, Lawyer & Trade Mark Attorney.
4 Pearce IP Patent Professionals Ranked in Managing IP’S IP STARS 2026, including Naomi Pearce and Helen Macpherson, who have been named Patent Stars in Australia; and Jacinta Flattery-O’Brien (Australia), and Paul Johns (New Zealand), who have been recognised as Notable Practitioners.
Pearce IP has been ranked by Managing IP in the 2026 Asia-Pacific IP Stars for Patent Prosecution, Patent Disputes and Trade Mark Prosecution, marking the sixth consecutive year of rankings for the Australian office and the first for Pearce IP New Zealand which was founded in 2024.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 19 June 2026 are set out below…
Pearce IP is pleased to announce the appointment of Peter O’Sullivan as Executive, Deputy CEO & Head of People and Culture. Peter is an experienced C-suite professional services executive, and joins Pearce IP with more than 30 years’ experience spanning human resources, business and law.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 12 June 2026 are set out below…
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.
